Frontiers in Clinical Drug Research - Dementia is a book series which presents comprehensive reviews about research on Dementia, - the loss of brain function associated with Alzheimer’s disease and other related medical conditions. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for dementia and related disorders. This volume includes the following reviews: - Meeting the Challenges of Falls and Hip Fractures in People with Alzheimer’s Disease - Cholesterol in Brain Health and Pathologies - Advances in the Treatment of Mild Cognitive Impairment (MCI) and Dementia - Analytical Methods in Alzheimer’s Disease Drug Discovery - Targeting Alzheimer’s Disease through Nanomedicine - Current Challenges in Alzheimer’s Disease Research - Metals Linked to Alzheimer's Disease

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology. This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include: - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions - Tau-targeted therapy in Alzheimer's disease - history and current state - Emerging nanotherapeutic strategies in Alzheimer's disease - Implication of dehydroepiandrosterone on dementia related to oxidative stress - Polyphenol compounds as potential therapeutic agents in Alzheimer’s disease The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.

Frontiers in Clinical Drug Research - Alzheimer Disorders is an e-Book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimers Disease research.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.

Frontiers in Clinical Drug Research - Anti-Allergy Agents is a book series comprising of a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs. The fifth volume of this series brings 5 reviews which cover the following topics: - Resistin: an irresistible therapeutic target for inflammatory diseases, allergy-related disorders, and cancer- Asthma in adults: evaluation, prevalence, and its clinical management- Nitrogen-containing heterocycles as anti-allergy agents- Experimental and clinical studies on the effects of nigella sativa and its constituents on allergic and immunological disorders- Aspirin desensitization/challenge in patients with cardiovascular diseases: current trends and advances Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field

Societies around the world are concerned about dementia and the other forms of cognitive impairment that affect many older adults. We now know that brain changes typically begin years before people show symptoms, which suggests a window of opportunity to prevent or delay the onset of these conditions. Emerging evidence that the prevalence of dementia is declining in high-income countries offers hope that public health interventions will be effective in preventing or delaying cognitive impairments. Until recently, the research and clinical communities have focused primarily on understanding and treating these conditions after they have developed. Thus, the evidence base on how to prevent or delay these conditions has been limited at best, despite the many claims of success made in popular media and advertising. Today, however, a growing body of prevention research is emerging. Preventing Cognitive Decline and Dementia: A Way Forward assesses the current state of knowledge on interventions to prevent cognitive decline and dementia, and informs future research in this area. This report provides recommendations of appropriate content for inclusion in public health messages from the National Institute on Aging.

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The first volume of the series features 9 chapters that cover a variety of therapeutic areas such as: -advances in the treatment of cerebral gliomas, multiple sclerosis and schizophrenia, -different uses for antidepressants in treating drug users and adolescents suffering from depression, -research on epilepsy and autism spectrum disorder therapy -advances in the treatment of cerebral gliomas, multiple sclerosis and schizophrenia, -different uses for antidepressants in treating drug users and adolescents suffering from depression, -research on epilepsy and autism spectrum disorder therapy.

Frontiers in Clinical Drug Research – Central Nervous System presents the latest research and clinical studies on the central nervous system (CNS). It covers a range of topics such as the development and pathophysiology of the brain and spinal cord, physiological sites of drug action in the CNS and clinical findings on drugs used to treat CNS defects due to injury or impaired development. In addition to clinical research on humans, the book also highlights other avenues of CNS medicine and research such as pain medicine, stem cell research, pharmacology, toxicology and translational models in animals. The first volume of the series features chapters on the following topics: -Nerve targets in pain medicine -Spinal cord injury -Research on neurotoxins targeting voltage gated ion channels -G protein coupled receptor agonists and modulators -Drug research on mediating hypoxia in developing white matter

Frontiers in Clinical Drug Research – Hematology is an eBook series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of hematological disorders. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of anemias, coagulopathies, vascular diseases and hematological malignancies. Reviews in this series also include research on specific antibody targets, therapeutic methods, genetic hemoglobinopathies and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Hematology is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of hematology, oncology and vascular pharmacology. The first volume of this series features 6 chapters that cover a variety of topics including: Computational methods, molecular docking, and molecular dynamics simulation Recent advances in the treatment of Beta-Thalassemia Major Research on multiple myeloma and leukemia Molecular imaging in hematology

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in neurology and allied disciplines. The twelfth volume of this series features these reviews: Chapter 1: Recent Drugs Tested in Clinical Trials for Alzheimer's and Parkinson's Diseases Treatment: Current Approaches in Tracking New Drugs Chapter 2: Neurobiology of Placebo: Interpreting Its Evolutionary Origin, Meaning, Mechanisms, Monitoring, and Implications in Therapeutics Chapter 3: Role of Gut Microbiota in Neuroinflammation and Neurological Disorders Chapter 4: The Role of Age in Pediatric Tumors of the Central Nervous System Chapter 5: Drug Repurposing in CNS and Clinical Trials: Recent Achievements and Perspectives Focusing on Epilepsy and Related Comorbidities Chapter 6: Progress on the Development of Oxime Derivatives as a Potential Antidote for Organophosphorus Poisoning Readership Pharmaceutical scientists, clinical researchers, medical consultants and allied healthcare professionals interested in neuropharmacology and neurology